A Phase 2 interventional study of Recombinant birch pollen in Birch Pollen Allergy, sponsored by Allergopharma GmbH & Co. KG. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-03-04.
Sponsored by Allergopharma GmbH & Co. KG · Phase 2, Interventional, and Treatment
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
392 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 25 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →Allergopharma GmbH & Co. KG is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergopharma GmbH & Co. KG